36.3 Uterine Motility Drugs and Lactation Considerations

Uterine Motility Drugs

Uterine motility drugs give providers control over the timing and progression of labor. Oxytocics stimulate uterine contractions, while tocolytics inhibit them. Understanding both categories, their mechanisms, and their risks is essential for safe nursing care during labor, delivery, and the postpartum period.

Oxytocics: Stimulating Uterine Contractions

Oxytocics are used to induce or augment labor and to manage postpartum hemorrhage. There are two main subgroups:

Oxytocin

• Oxytocin is a naturally produced posterior pituitary hormone that triggers uterine contractions.
• Pitocin is the synthetic IV form. It's the most commonly used drug for labor induction and augmentation, and it's also given postpartum to control uterine bleeding by promoting uterine tone.

Prostaglandins

• Prostaglandins promote both cervical ripening (softening and thinning) and uterine contractions.
• Dinoprostone is available as a vaginal insert (Cervidil) or vaginal gel (Prepidil), typically used for cervical ripening before oxytocin induction.
• Misoprostol (Cytotec) is an oral or vaginal tablet. Its use for labor induction is off-label, but it's widely used because it's inexpensive and effective. Nurses should be aware of the off-label status and follow facility protocols closely.

Tocolytics: Inhibiting Uterine Contractions

Tocolytics are used to suppress preterm labor contractions. The goal isn't to stop labor permanently; it's to buy time (usually 48 hours) so corticosteroids can be given to accelerate fetal lung maturity and the patient can be transferred to a facility with a higher-level NICU if needed.

Several drug classes are used as tocolytics:

• Magnesium sulfate is given as an IV infusion. It acts as a muscle relaxant and also provides fetal neuroprotection against cerebral palsy in preterm births. This is one of the most commonly used tocolytics.
• Nifedipine (a calcium channel blocker) is given orally. It reduces calcium influx into smooth muscle cells, decreasing contraction strength and frequency.
• Terbutaline (a beta-2 adrenergic agonist) relaxes uterine smooth muscle. It's given subcutaneously for acute tocolysis. The FDA has issued a warning against prolonged oral or injectable use beyond 48–72 hours due to the risk of serious maternal cardiac events.
• Indomethacin (an NSAID) inhibits prostaglandin synthesis. It's generally limited to use before 32 weeks' gestation because prolonged use can cause premature closure of the fetal ductus arteriosus.

Effects, Uses, and Risks

Nursing Care for Patients on Uterine Motility Drugs

1. Assessment

• Monitor maternal vital signs: blood pressure, pulse, respirations
• Continuously assess uterine activity: contraction frequency, duration, intensity, and resting tone between contractions
• Monitor fetal heart rate (FHR) tracing: baseline rate, variability, accelerations, and decelerations
• Assess cervical status: dilation, effacement, and station
• Note vaginal discharge (bloody show, fluid leakage) and the patient's pain level

2. Planning

• Collaborate with the obstetric provider to select appropriate drug therapy based on maternal/fetal indications and contraindications
• Establish clear goals, such as achieving adequate contraction pattern (typically every 2–3 minutes lasting 60–90 seconds for oxytocin) or successfully delaying delivery for tocolytic patients
• Plan for pain management alongside uterine motility drug therapy

3. Implementation

• Administer medications as prescribed via the correct route (IV infusion pump for oxytocin and magnesium sulfate; oral or vaginal for prostaglandins and nifedipine; subcutaneous for terbutaline)
• For oxytocin: always use an infusion pump, piggyback the oxytocin into a mainline IV so it can be discontinued quickly, and titrate per protocol
• For magnesium sulfate: have calcium gluconate at the bedside as the antidote for magnesium toxicity; monitor deep tendon reflexes, urine output (should be ≥30 mL/hr), and respiratory rate (hold if <12 breaths/min)
• Provide supportive care: positioning, hydration, emotional support, and non-pharmacologic comfort measures (breathing techniques, massage)
• Educate the patient and family on what the drug does, how it's given, expected effects, and what to report

4. Evaluation

• For oxytocics: Are contractions regular and producing cervical change? Is the FHR tracing reassuring (Category I)?
• For tocolytics: Have contractions decreased in frequency and intensity? Has delivery been delayed long enough for corticosteroids to take effect (optimally 48 hours)?
• Watch for adverse reactions:
  • Uterine hyperstimulation (contractions lasting >90 seconds, occurring more frequently than every 2 minutes, or inadequate resting tone). If this occurs with oxytocin: stop the infusion, position the patient on her left side, administer oxygen, increase the mainline IV rate, and notify the provider.
  • Maternal tachycardia, hypotension, or signs of magnesium toxicity
  • Non-reassuring FHR patterns (late decelerations, absent variability, prolonged bradycardia)
• Adjust the care plan based on patient response: modify dosage, change medications, provide emergency interventions, or prepare for cesarean delivery if needed

Lactation Considerations and Patient Education

Patient Education on Uterine Motility Drugs

Effective patient education covers these key areas:

• Why the drug is being used: Explain the indication clearly. For oxytocin, that might be "your labor needs a boost to progress safely." For tocolytics, "we're trying to slow your contractions to give your baby more time to develop."
• How it's given: Describe the route (IV drip, pill, vaginal insert) and what the patient will experience (e.g., contractions may feel stronger and closer together with oxytocin).
• What to expect: Continuous fetal monitoring will be in place. Frequent cervical exams may be needed to track progress.
• What to report immediately:
  • Sudden, severe pain or contractions that don't let up
  • Excessive vaginal bleeding
  • Feeling dizzy, short of breath, or a racing heartbeat
  • Decreased fetal movement
  • Chest pain or tightness (especially with tocolytics)

Evaluating Medication Safety for Mother and Fetus

Before starting any uterine motility drug, the nurse should verify several safety factors:

• Medication history and allergies: Screen for contraindications or drug interactions. For example, prostaglandins are contraindicated in patients with a history of asthma (bronchospasm risk).
• Gestational age and fetal status: Confirm fetal viability and assess lung maturity when relevant. Indomethacin, for instance, is generally avoided after 32 weeks due to the risk of premature ductus arteriosus closure.
• Maternal contraindications: These vary by drug. Oxytocin is contraindicated in cases of placenta previa, vasa previa, cord prolapse, or prior classical uterine incision. Active genital herpes is a contraindication to vaginal delivery (and therefore to labor induction).
• Ongoing monitoring: Continuously reassess the risk-benefit ratio. If the maternal or fetal status changes, the medication regimen may need to be adjusted or discontinued.

Advising on Medication Use During Breastfeeding

Many patients on uterine motility drugs will transition to breastfeeding postpartum. Nurses should be prepared to address medication safety during lactation:

• Use reliable references: LactMed (a free NIH database) and Medications and Mothers' Milk (Hale's) are the gold-standard resources for drug safety in breastfeeding. Don't rely on the package insert alone, as many list breastfeeding as a precaution by default.
• Drug properties that increase milk transfer: Low molecular weight, high lipid solubility, low protein binding, and long half-life all increase the amount of drug that passes into breast milk.
• Infant risk factors: Premature infants, low-birth-weight infants, and those with impaired renal or hepatic function are more vulnerable to drug effects through breast milk.
• Practical strategies to reduce infant exposure:
  • Time breastfeeding to avoid peak maternal serum drug concentrations when possible
  • Consider pump-and-dump only when specifically indicated (this is less common than many patients assume)
  • Recommend safer alternatives when available. Oxytocin, for example, has minimal oral bioavailability in the infant and is considered compatible with breastfeeding.
• Monitor the infant: Watch for sedation, poor feeding, irritability, or changes in stool patterns. Track growth and weight gain at follow-up visits.
• Support shared decision-making: Encourage patients to discuss breastfeeding goals and medication concerns openly with their provider. The decision to breastfeed while on a medication should weigh the benefits of breastfeeding against the potential (often small) risk of infant drug exposure.